Management of Knee Hematoma After Fall in Patient on Eliquis
For a knee hematoma after a fall in a patient taking Eliquis (apixaban), you should immediately assess whether this is a major or non-major bleed, temporarily hold the Eliquis, apply local compression, and provide supportive care—reversal agents are NOT indicated for non-major extremity hematomas but should be considered only if there is hemodynamic instability, hemoglobin drop ≥2 g/dL, or transfusion requirement of ≥2 units. 1
Initial Assessment: Classify Bleed Severity
The 2020 ACC Expert Consensus provides a clear algorithmic approach 1:
A bleed is considered MAJOR if ANY of the following apply:
- Bleeding at a critical site (intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal)
- Hemodynamic instability
- Clinically overt bleeding with hemoglobin decrease ≥2 g/dL
- Administration of ≥2 units of red blood cells
If NONE of these criteria are met, the bleed is NON-MAJOR.
A simple knee hematoma from a fall, without the above features, is typically a non-major bleed.
Management Based on Bleed Classification
For Non-Major Knee Hematoma (Most Likely Scenario):
Immediate Actions:
- Stop Eliquis temporarily 1
- Provide local therapy/manual compression to the knee 1
- Do NOT administer reversal/hemostatic agents (andexanet alfa, PCC) for non-major bleeds 1
- Provide supportive care and volume resuscitation as needed
- Assess for comorbidities that could contribute to bleeding (thrombocytopenia, uremia, liver disease, concomitant antiplatelet agents) 1
- Review Eliquis dosing appropriateness for patient's renal function and other medications 1
Key Pitfall: The French guidelines suggest that non-severe bleeding on DOACs generally resolves spontaneously with symptomatic treatment and should prompt a review of treatment modalities 2. Overuse of reversal agents in non-major bleeds exposes patients to unnecessary thrombotic risk.
For Major Knee Hematoma (If Criteria Met):
If the hematoma causes hemodynamic instability, significant hemoglobin drop, or compartment syndrome:
Immediate Actions:
- Stop Eliquis and any antiplatelet agents 1
- Provide local therapy/manual compression
- Provide supportive care and volume resuscitation
- Consider surgical/procedural management if compartment syndrome develops 1
Reversal Agent Consideration:
- Andexanet alfa is the specific reversal agent for apixaban 1
- If andexanet alfa unavailable: Consider 4-factor PCC (25-50 IU/kg) or activated PCC 1, 2
- Consider activated charcoal if apixaban was taken within 2-4 hours 1
Important Caveat: The French guidelines note that for non-intracranial hemorrhage, PCC dosing of 25-50 IU/kg is suggested, with 50 IU/kg reserved for hemorrhagic shock 2. The threshold for reversal should be a plasma apixaban concentration >50 ng/mL for non-intracranial bleeds 2.
When to Restart Eliquis
Once the patient is stable, assess whether to restart anticoagulation 1:
DELAY or DISCONTINUE restart if ANY of the following:
- High risk of rebleeding or death/disability with rebleeding
- Source of bleed not yet identified
- Surgical or invasive procedures planned
- Patient does not wish to restart at this time
RESTART anticoagulation if:
- None of the above factors apply
- There is a continued clinical indication for anticoagulation (e.g., atrial fibrillation, VTE treatment)
- Adequate hemostasis has been established 3
Timing Considerations:
- Apixaban has a half-life of 6-15 hours (up to 17 hours in severe renal impairment) 1
- The pharmacodynamic effect persists for at least 24 hours after the last dose 3
- For elective procedures with moderate-high bleeding risk, hold Eliquis for at least 48 hours; for low bleeding risk, hold for at least 24 hours 3
Monitoring and Follow-up
Important Notes:
- Standard coagulation tests (PT, INR, aPTT) are not useful for monitoring apixaban effect 3
- Anti-factor Xa activity can be measured but is not routinely necessary for clinical decision-making 4
- Hemodialysis does not substantially impact apixaban exposure 3
- Protamine sulfate and vitamin K are not effective for reversing apixaban 3
Special Considerations
Concomitant Medications:
- SSRIs (like citalopram) can synergistically increase bleeding risk with apixaban 5
- Antiplatelet agents significantly increase bleeding complications 1, 6
- Combined P-gp and strong CYP3A4 inhibitors increase apixaban levels 3
Renal Function:
- Acute kidney injury increases apixaban exposure and bleeding risk 6
- Dose adjustment may be needed based on creatinine clearance 1
Real-World Context: Case reports document various hematomas (limb-threatening, thigh, rectus sheath) in patients on apixaban 5, 7, 8, 9, emphasizing the importance of early recognition and prompt conservative management for non-major bleeds, reserving reversal agents for truly life-threatening situations.